{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"description":"Evaluation of the ability to successfully collect peripheral blood stem cells following four months (cycles) of combination therapy.","groups":[{"description":"Bortezomib 1.3mg/m\\^2 by IV days 1, 4, 8 \\& 11\n\nCyclophosphamide 300mg/m\\^2 PO days 1, 8, 15 \\& 22\n\nDexamethasone 40mg PO days 1-4, 9-12, 17-20","id":"OG000","title":"CyBorD (Bortezomib 1.3mg/m^2)"},{"description":"Bortezomib 1.5mg/m\\^2 by IV days 1, 8, 15 \\& 22\n\nCyclophosphamide 300mg/m\\^2 PO days 1, 8, 15 \\& 22\n\nDexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 \\& 22","id":"OG001","title":"CyBorD (Bortezomib 1.5mg/m^2)"}],"paramType":"NUMBER","populationDescription":"At the time of publication, data was available on 18 patients for group 2.","reportingStatus":"POSTED","timeFrame":"After 4 cycles of treatment","title":"Participants Who Successfully Completed Collection of Peripheral Blood Stem Cells for Transplant","type":"SECONDARY","unitOfMeasure":"participants"}